U.S. Actinic Keratosis Treatment Market Worth $2.94 Billion By 2030

U.S. Actinic Keratosis Treatment Market Growth & Trends

The U.S. actinic keratosis treatment market size is expected to reach USD 2.94 billion by 2030, expanding at a CAGR of 3.03% over the forecast period, according to a new report by Grand View Research, Inc. The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.

The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.

Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.

According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.

Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp. 

 Request a free sample copy or view report summary: U.S. Actinic Keratosis Treatment Market Report

U.S. Actinic Keratosis Treatment Market Report Highlights

• The surgery segment held the largest share owing to the higher demand for complete disease eradication and high penetration of cryotherapy procedures

• The photodynamic therapy segment registered the fastest growth rate because of high site specificity and less incidence of side effects

• The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease

• Based on product, the 5-fluorouracil segment dominated the U.S. actinic keratosis treatment market in 2022, whereas, the tirbanibulin segment is anticipated to be the fastest-growing segment

• The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals

• Key players dominating the market include Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A.; and Biofrontera AG

U.S. Actinic Keratosis Treatment Market Segmentation

Grand View Research has segmented the U.S. actinic keratosis treatment market based on therapy, drug class, product, and end-use:

U.S. Actinic Keratosis Treatment Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Topical/Drugs

• Surgery

  • Cryotherapy
  • Others

• Photodynamic Therapy

U.S. Actinic Keratosis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleoside metabolic inhibitors

• Nonsteroidal anti-inflammatory drugs

• Immune response modifiers

• Photoenhancers

• Others

U.S. Actinic Keratosis Treatment Product Outlook (Volume, Number of Units Sold; Revenue, USD Million, 2018 - 2030)

• 5-fluorouracil

  • Carac

  • Fluoroplex

  • Actikerall

  • Tolak

  • Others

• Diclofenac

  • Solaraze

  • Voltaren

  • Pennsaid

  • Others

• Imiquimod

  • Aldara

  • Zyclara

  • Others

• Tirbanibulin

• Capecitabine

  • Xeloda

  • Others

• Aminolevulinic acid

  • Ameluz

  • Levulan

• Porfimer sodium

• Others

  • Gemzar

  • Clolar

  • Vidaza

  • Metvix

  • Others

U.S. Actinic Keratosis Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Private clinics

• Homecare

• Others

List of Key Players in the U.S. Actinic Keratosis Treatment Market

• Bausch Health Companies, Inc.

• LEO Pharma A/S

• Almirall, S.A

• Biofrontera AG

• GALDERMA

• Sun Pharmaceutical Industries Ltd

• Novartis AG

• Hill Dermaceuticals, Inc.

• 3M

• Viatris, Inc.